Zelquistinel
Major Depressive Disorder (MDD)
Key Facts
About Syndeio Biosciences
Syndeio Biosciences is a private, clinical-stage biotech developing synapse-targeted therapeutics for disorders like major depressive disorder (MDD) and Alzheimer's disease. Its core innovation is the Boost Platform™, a proprietary synapse pharmacology model originating from Nobel laureate Thomas Südhof's lab, which it uses to discover and characterize novel positive allosteric modulators (PAMs) of the NMDA receptor. The company's lead assets, zelquistinel (oral) and apimostinel (injectable), are in Phase 2 trials, with a focus on establishing rapid-acting, durable efficacy with improved safety profiles compared to existing NMDAR-targeted therapies. Syndeio is strategically leveraging precision neuroscience tools and biomarkers to de-risk clinical development in large, underserved patient populations.
View full company profileAbout Syndeio Biosciences
Syndeio Biosciences is a private, clinical-stage biotech developing synapse-targeted therapeutics for disorders like major depressive disorder (MDD) and Alzheimer's disease. Its core innovation is the Boost Platform™, a proprietary synapse pharmacology model originating from Nobel laureate Thomas Südhof's lab, which it uses to discover and characterize novel positive allosteric modulators (PAMs) of the NMDA receptor. The company's lead assets, zelquistinel (oral) and apimostinel (injectable), are in Phase 2 trials, with a focus on establishing rapid-acting, durable efficacy with improved safety profiles compared to existing NMDAR-targeted therapies. Syndeio is strategically leveraging precision neuroscience tools and biomarkers to de-risk clinical development in large, underserved patient populations.
View full company profileTherapeutic Areas
Other Major Depressive Disorder (MDD) Drugs
| Drug | Company | Phase |
|---|---|---|
| AL001 | Alzamend Neuro | Preclinical |
| Deep TMS (H1 Coil) | BrainsWay | FDA Cleared |
| EXXUA™ (gepirone ER) | Aytu BioPharma | Commercial |
| ZZ6398 | Zhongze Therapeutics | Phase 1/2 |
| INV-202 (Oral & LAI) | Indivior | Preclinical |
| NeuroStar Advanced Therapy | Neuronetics | FDA Cleared |
| Gepirone ER | Fabre-Kramer Pharmaceuticals | NDA Submitted |
| Exablate Neuro | Insightec | Clinical Trial |
| BrightKaire Platform for Depression | NeuroKaire | Pre-clinical |
| Tyemvers (CKDB-501) | Healis Therapeutics | Pre-clinical |
| VENTURA-7 | New Hope Clinical Research | Phase 2/3 |
| DT-101 | Draig Therapeutics | Phase 2 |